This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Neurology  • Multiple Sclerosis/ Demyelinating Disease  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

Dr Cantor raises several relevant questions regarding the post hoc analysis comparing AA and WA patients with multiple sclerosis and their responses to interferon beta-1a treatment from the EVIDENCE trial. The first question asks whether the difference observed between the 2 groups could be accounted for by differences in the proportions of patients treated with once weekly vs thrice weekly interferon beta-1a. We addressed this issue by performing multivariate analysis that adjusted for treatment and reported comparable results to the unadjusted analysis. We conclude that the differences observed between the 2 groups were not accounted for by differences in the dose and frequency of interferon beta-1a administration.

The second question raised is whether a few outliers in the AA group skewed the results. We did not find this to be the case. Indeed, the standard deviations of the outcome variables were very similar between the 2 groups. Furthermore, . . . [Full Text of this Article]

AUTHOR INFORMATION

Bruce A. C. Cree, MD, PhD, MCR

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Interferon Beta-1a Treatment and African Americans
Fredric K. Cantor
Arch Neurol. 2006;63(4):627-628.
EXTRACT | FULL TEXT